At the first signs of a cold, standardized extract several times a day.
No clear effect on infections — null/mixed result
View the study (meta-analysis) →⏱ 2 min read
Echinacea is a plant native to the North American prairies that was used traditionally by Indigenous peoples for infections, bites, and wounds, and popularized in the 20th century in Europe (especially Germany) as a remedy for colds and seasonal respiratory infections; modern research has confirmed a modest but replicable effect in preventing and shortening the common cold, with an immunomodulatory activity profile documented in mechanistic studies.
There are three main medicinal species with slightly different profiles: Echinacea purpurea (the most studied clinically), Echinacea angustifolia, and Echinacea pallida; quality products use aerial parts, roots, or both, fresh or dried, and clinical efficacy depends on the specific extract and dosage, which explains the enormous variability of results among studies using heterogeneous products.
Several meta-analyses have shown that echinacea reduces the risk of catching a cold by 10 to 35 percent with preventive use (several weeks during the highest-risk season) and shortens the duration of an established cold by 1 to 4 days when started from the first symptoms; the effects are modest but consistent with standardized products such as Echinaforce (a fresh-plant extract of E. purpurea), where the data are more reproducible.
The most plausible mechanism combines stimulation of the phagocytic activity of macrophages, cytokine modulation, and a possible direct antiviral effect on some respiratory viruses (rhinovirus, influenza, common coronaviruses) documented in in vitro studies; these effects are quantitatively modest compared with a pharmacological antiviral but sufficient to reduce symptom burden in most people who take it at the first sneeze.
In people with a history of many colds (more than three a year), preventive supplementation for 4 to 6 months with 2,400 mg daily of standardized extract significantly reduced the frequency of episodes and the total days with symptoms in several randomized trials, especially in people whose immune systems are under strain (chronic stress, prolonged intense exercise, work involving frequent contact with children or patients).
In lower respiratory tract infections and bronchitis, the data are less solid but suggest modest adjunctive effects; in wounds and dermatitis, echinacea creams have some evidence of accelerating healing although the studies are small; in recurrent urinary tract infections there are interesting preliminary data that require confirmation.
For therapeutic use at the first symptom of a cold, effective doses are 800-2,400 mg daily of standardized extract or the equivalent in tincture (5-10 ml/day) for 7-10 days; for preventive use during the highest-risk season, lower doses (400-800 mg/day) for 8-12 weeks with periodic breaks; fresh-plant products (especially Echinaforce) have more clinical support than generic dried-plant ones.
Generally well tolerated in short-term use; the most frequent adverse effects are mild digestive discomfort, occasionally allergic reactions in people sensitive to plants of the Asteraceae family (chamomile, ragweed, chrysanthemum); it is contraindicated in people with active autoimmune diseases (lupus, multiple sclerosis, rheumatoid arthritis during a flare) because its theoretical immunostimulant effect may be counterproductive; immunosuppressed people or those taking immunosuppressants should avoid it for the same reason.
Information, not medical advice. Scientific evidence reflects the quality of the studies.